Sign in or create an account to add this stock to your watchlist.
About Polydex Pharmaceuticals (OTCMKTS:POLXF)
Polydex Pharmaceuticals Limited, through its subsidiaries, manufactures bulk pharmaceutical intermediates for the veterinary pharmaceutical industry worldwide. It also develops, manufactures, and markets biotechnology-based products for the human pharmaceutical market. The company primarily offers dextran and derivative products, including Iron Dextran, a derivative of dextran that is injected into pigs at birth as a treatment for anemia; and dextran sulphate, a specialty chemical derivative of dextran used in biotechnology applications and the pharmaceutical industry. It also provides ferric hydroxide and hydrogenated dextran to Sparhawk Laboratories Inc. In addition, the company develops Ushercell, a high molecular weight cellulose sulphate for topical vaginal use primarily in the prevention and transmission of AIDS and other sexually transmitted diseases, as well as unplanned pregnancies; and Usherdex 4, a low molecular weight dextran product for the treatment of cystic fibrosis, a genetic disease. Polydex Pharmaceuticals Limited sells its iron dextran primarily to independent distributors and wholesalers primarily in Europe, the Far East, South America, and Canada; and Dextran Sulphate to independent distributors or companies in the United States and Europe for analytical applications. The company was formerly known as Polydex Chemicals Limited and changed its name to Polydex Pharmaceuticals Limited in March 1984. Polydex Pharmaceuticals Limited was founded in 1966 and is based in Toronto, Canada.
Industry, Sector and Symbol
Industry Industrial inorganic chemicals
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:POLXF
CUSIPN/A
Phone416-755-2231
Debt
Debt-to-Equity Ratio0.05
Current Ratio4.27
Quick Ratio3.15
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.28 million
Price / Sales0.73
Cash Flow$0.2065 per share
Price / Cash5.52
Book Value$1.70 per share
Price / Book0.67
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$440,000.00
Net Margins8.32%
Return on Equity8.19%
Return on Assets6.36%
Miscellaneous
EmployeesN/A
Outstanding Shares3,380,000
Polydex Pharmaceuticals (OTCMKTS:POLXF) Frequently Asked Questions
What is Polydex Pharmaceuticals' stock symbol?
Polydex Pharmaceuticals trades on the OTCMKTS under the ticker symbol "POLXF."
How were Polydex Pharmaceuticals' earnings last quarter?
Polydex Pharmaceuticals Limited (OTCMKTS:POLXF) announced its quarterly earnings results on Tuesday, May, 1st. The company reported $0.03 earnings per share for the quarter. The firm had revenue of $1.31 million for the quarter. Polydex Pharmaceuticals had a return on equity of 8.19% and a net margin of 8.32%. View Polydex Pharmaceuticals' Earnings History.
When is Polydex Pharmaceuticals' next earnings date?
Who are some of Polydex Pharmaceuticals' key competitors?
Some companies that are related to Polydex Pharmaceuticals include Praxair (PX), Air Products & Chemicals (APD), JSR (JSCPY), Kronos Worldwide (KRO), Minerals Technologies (MTX), Valhi (VHI), Tronox (TROX), Venator Materials (VNTR), NL Industries (NL), Luxfer (LXFR), LSB Industries (LXU) and Hydrogenics (HYGS).
Who are Polydex Pharmaceuticals' key executives?
Polydex Pharmaceuticals' management team includes the folowing people:
- Mr. George G. Usher, Chairman, CEO, Pres, Pres of Chemdex Inc and VP of Dextran Products Ltd (Age 59)
- Mr. John Alfred Luce C.A., Chief Financial Officer and Principal Accounting Officer (Age 71)
- Ms. Sharon L. Wardlaw, Chief Operating Officer, Treasurer, Sec. and Pres of Dextran Products Limited (Age 65)
Has Polydex Pharmaceuticals been receiving favorable news coverage?
News articles about POLXF stock have been trending somewhat positive on Friday, Accern reports. Accern scores the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Polydex Pharmaceuticals earned a media sentiment score of 0.18 on Accern's scale. They also assigned news stories about the company an impact score of 47.20 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Polydex Pharmaceuticals?
Shares of POLXF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Polydex Pharmaceuticals' stock price today?
One share of POLXF stock can currently be purchased for approximately $1.14.
How big of a company is Polydex Pharmaceuticals?
Polydex Pharmaceuticals has a market capitalization of $3.85 million and generates $5.28 million in revenue each year.
How can I contact Polydex Pharmaceuticals?
Polydex Pharmaceuticals' mailing address is 421 COMSTOCK ROAD, TORONTO A6, M1L 2H5. The company can be reached via phone at 416-755-2231.
MarketBeat Community Rating for Polydex Pharmaceuticals (POLXF)
MarketBeat's community ratings are surveys of what our community members think about Polydex Pharmaceuticals and other stocks. Vote "Outperform" if you believe POLXF will outperform the S&P 500 over the long term. Vote "Underperform" if you believe POLXF will underperform the S&P 500 over the long term. You may vote once every thirty days.
Polydex Pharmaceuticals (OTCMKTS:POLXF) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 5/25/2016 forward)
Polydex Pharmaceuticals (OTCMKTS:POLXF) Earnings History and Estimates Chart
Polydex Pharmaceuticals (OTCMKTS POLXF) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 8/7/2018 | | | | | | | | |
| 5/1/2018 | Q4 2018 | | $0.03 | | $1.31 million | View | N/A |  |
| 12/15/2017 | Q3 2018 | | $0.07 | | $1.44 million | View | N/A | |
| 5/1/2017 | Q4 2017 | | $0.02 | | $1.98 million | View | N/A | |
| 12/15/2016 | Q3 2017 | | $0.07 | | $1.45 million | View | N/A | |
| 9/15/2016 | Q2 2017 | | $0.08 | | $1.74 million | View | N/A | |
| 6/14/2016 | Q1 2017 | | $0.02 | | $1.46 million | View | N/A | |
| 5/2/2016 | Q4 2016 | | $0.04 | | $1.38 million | View | N/A | |
| 12/15/2015 | Q3 2016 | | $0.12 | | $1.42 million | View | N/A | |
| 9/15/2015 | Q2 2016 | | $0.12 | | $1.68 million | View | N/A | |
| 6/10/2015 | Q1 2016 | | $0.09 | | $1.56 million | View | N/A | |
| 4/30/2015 | Q4 2015 | | $0.09 | | $1.39 million | View | N/A | |
| 12/15/2014 | Q3 2015 | | $0.03 | | $1.30 million | View | N/A | |
| 9/9/2014 | Q2 2015 | | $0.02 | | $1.27 million | View | N/A | |
| 6/10/2014 | Q1 2015 | | $0.02 | | $1.41 million | View | N/A | |
| 5/1/2014 | Q4 2014 | | $0.04 | | $1.34 million | View | N/A | |
| 12/11/2013 | Q3 | | $0.01 | | $1.32 million | View | N/A | |
| 9/16/2013 | Q2 2014 | | $0.06 | | $1.87 million | View | N/A | |
| 6/10/2013 | Q1 2014 | | $0.08 | | $1.44 million | View | N/A | |
| 4/30/2013 | Q4 2013 | | ($0.02) | | $1.50 million | View | N/A | |
| 12/14/2012 | Q3 2013 | | ($0.04) | | | View | N/A | |
| 9/17/2012 | Q2 2013 | | ($0.03) | | | View | N/A | |
| 6/15/2012 | Q1 2013 | | ($0.04) | | | View | N/A | |
| 4/30/2012 | Q4 2012 | | ($0.02) | | | View | N/A | |
| 12/15/2011 | Q3 2012 | | $0.03 | | | View | N/A | |
| 6/13/2011 | Q1 2012 | | $0.05 | | | View | N/A | |
| 5/4/2011 | Q4 2011 | | ($0.08) | | | View | N/A | |
| 12/15/2010 | Q3 2011 | | ($0.01) | | | View | N/A | |
| 9/15/2010 | Q2 2011 | | ($0.11) | | | View | N/A | |
| 6/15/2010 | Q1 2011 | | ($0.03) | | | View | N/A | |
| 5/3/2010 | Q4 2010 | | ($0.45) | | | View | N/A | |
| 12/15/2009 | Q3 2010 | | ($0.07) | | | View | N/A | |
| 9/14/2009 | Q2 2010 | | ($0.16) | | | View | N/A | |
| 6/15/2009 | Q1 2010 | | ($0.02) | | | View | N/A | |
| 12/12/2008 | Q3 2009 | | ($0.14) | | | View | N/A | |
| 9/12/2008 | Q2 2009 | | ($0.04) | | | View | N/A | |
| 6/13/2008 | Q1 2009 | | ($0.01) | | | View | N/A | |
| 4/30/2008 | Q4 2008 | | ($0.11) | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Polydex Pharmaceuticals (OTCMKTS:POLXF) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Polydex Pharmaceuticals (OTCMKTS POLXF) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 12.90%
Polydex Pharmaceuticals (OTCMKTS POLXF) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
Polydex Pharmaceuticals (OTCMKTS POLXF) News Headlines
| Source: |
|
Polydex Pharmaceuticals (OTCMKTS:POLXF) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Polydex Pharmaceuticals (OTCMKTS:POLXF) Income Statement, Balance Sheet and Cash Flow Statement
Polydex Pharmaceuticals (OTCMKTS POLXF) Stock Chart for Friday, May, 25, 2018
Loading chart…
